When We Talks

ARCH Venture Partners raises close to $3B for early-stage biotech fund – GeekWire


ARCH Venture Partners has closed a $2.975 billion fund targeted for early-stage biotech companies. The firm’s 12th venture fund comes on the heels of a nearly $2 billion fund announced in January 2021 and launches amidst a biotech bear market. “Science doesn’t care what markets are doing, and science moves forward,” said ARCH cofounder and managing director Robert Nelsen in a statement announcing the fund Wednesday. ARCH has offices in Seattle and is a backer of Seattle-area giants Sana Biotechnology and Lyell Immunopharma. ARCH was also a key investor in Seattle’s Juno Therapeutics, which was acquired by Celgene in 2018 in a deal worth more than $9 billion.


Source link

Related posts

REI reveals 6 startups for new accelerator that promotes founders of color – GeekWire

Effie Weber

Most popular stories on GeekWire for the week of July 10, 2022 – GeekWire

Effie Weber

Amazon Web Services releases upgraded Mac EC2 instances – GeekWire

Effie Weber